ConMed (NSDQ:CNMD) said it’s closed its 27¢-per-share tender offer for Viking Systems (OTC:VKNG), leaving it with about 84% of shares in the medical imaging maker.
ConMed closes tender offer for Viking Systems | Wall Street Beat
Viking Systems Inc.
ConMed lays out $23M for Viking Systems
Varian and Siemens launch global radiosurgery deal | Wall Street Beat
BD to deal labware biz to Corning for $730M | Wall Street Beat
Becton Dickinson & Co. (NYSE:BDX) said it agreed to sell its BD Biosciences – Discovery Labware unit to Corning Inc. (NYSE:GLW) for about $730 million in cash.
Boston Scientific launches Pluromed’s BackStop kidney stone treatment | Wall Street Beat
Boston Scientific (NYSE:BSX) launched its BackStop kidney stone treatment product in the U.S. and certain international markets this week.
Report: Covidien to acquire superDimension for $350M | Wall Street Beat
Covidien (NYSE:COV) is set to close a $350 million buyout of Israeli lung diagnosis firm superDimension by the end of the week, according to Israeli business journal Calcalist.
Founded in Tel Aviv by Pinchas Gilboa, Minneapolis-based superDimension, which employs about 120 people worldwide, also has offices in Dusseldorf, Germany.
Angeion narrows Q1 losses despite flat sales | Earnings Roundup
Angeion Corp. (NSDQ:ANGN) narrowed its 1st-quarter losses despite flat sales for the 3 months ended Jan. 31.
Although dragged down by a tough European climate, focusing on group purchasing organization and service revenues kept the company’s sales from sliding, the cardiorespiratory diagnostic systems maker said.
Bankers’ outlook grim for U.S. IPOs | Wall Street Beat
Bankers aren’t expecting much excitement in the U.S. market for initial public offerings this year, as China spends another year at the top.
About half of the 100 capital markets execs surveyed predict growth in IPOs this year, compared to 72% of those surveyed in advance of 2011, according to BDO USA, an accounting and consulting firm.
Only 16% of those surveyed expected any growth to be "significant," while 35% expect flat growth and 15% predicted that the market will continue to slide.
Covidien taps Quanterix CEO for board | Personnel Moves
Med-tech titan Covidien (NYSE:COV) named Quanterix Corp. CEO Martin Madaus to its board of directors.
Madaus, the former head of Millipore, was tapped by Quanterix in September for the corner office. His nomination, effective Dec. 1, is slated for a shareholder vote next year.
Smith & Nephew falls on softer orthopedic margins | Earnings Roundup
Lower margins for Smith & Nephew’s (NYSE:SNN) bread-and-butter orthopedics division drove the British company’s third-quarter profits down nearly 3 percent for the three months ended Oct. 1.
Smith & Nephew posted profits of $133 million, or 14.9 cents per share, on sales of $1.03 billion for the quarter – a top-line increase of 9.7 percent when compared with the $941 million in revenues reported for the same period last year. But Q3 2010 profits were $137 million, or 15.4 cents per share.
Medical device investment rose during Q2, even as deal volume fell | Wall Street Beat
Medical device investment deals got fatter and less frequent during the second quarter, as the value of deals grew 9 percent but their number slid 17 percent, according to PricewaterhouseCoopers.
Backers pumped $841 million into med-tech firms with 90 deals during the three months ended June 30, according to the consulting firm’s MoneyTree report. That’s up 26 percent and 3 percent, respectively, over the first quarter. The industry’s share of the venture capital cash spend on life sciences last quarter ticked down to 40 percent, however, compared with Q1 numbers.
